MicuRx and Cumencor Partner with Pfizer to Develop Antibiotics
publication date: Apr 6, 2010
MicuRx Pharmaceuticals, Inc., and Cumencor Pharmaceuticals, Inc. have formed a collaboration with Pfizer. The companies will seek to discover new drugs that treat multi-drug resistant tuberculosis (MDR-TB). Cumencor, a China-based biotech, applies MicuRx's proprietary technology to discover and develop novel antibiotics for MDR-TB. MicuRx, of Union City, CA and Shanghai, develops novel antibiotics to combat infections caused by resistant bacteria. MicuRx presented at the Inaugural ChinaBio® Investor Forum, held in Shanghai in December 2007. More details...
Stock Symbol: (NYSE: PFE)
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.